Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 515-528

  Bauwens, Andreas ^a   Bielaszewska, Martina ^a   Kemper, Björn ^a   Langehanenberg, Patrik ^a   Von Bally, Gert ^a   Reichelt, Rudolf ^a   Mulac, Dennis ^a   Humpf, Hans Ulrich ^a   Friedrich, Alexander W ^a   Kim, Kwang S ^b   Karch, Helge ^a   Müthing, Johannes ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Endothelial cells; Enterohaemorrhagic e. Coli; Necrosis; Shiga toxin; Single cell analysis

Indexed keywords

VEROTOXIN 1; VEROTOXIN 2;

APOPTOSIS; ARTICLE; BRAIN MICROCIRCULATION; CELL CULTURE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

APOPTOSIS; CELL PROLIFERATION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MICROCIRCULATION; MICROSCOPY, ELECTRON, SCANNING; NECROSIS; SHIGA TOXIN 1; SHIGA TOXIN 2;

EID: 79952531667     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0140     Document Type: Article

References (71)

1. Schnittler H, Preissner KT. Between microbial attack and defence: the endothelium as a vulnerable player in infectious diseases. Thromb Haemost 2009; 102: 1011-1013.
2. Lemichez E, Lecuit M, Nassif X, et al. Breaking the wall: targeting of the endothelium by pathogenic bacteria. Nat Rev Microbiol 2010; 8: 93-104.
3. Hippenstiel S, Suttorp N. Interaction of pathogens with the endothelium. Thromb Haemost 2003; 89: 18-24. (Pubitemid 36149788)
4. Karmali MA. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 2004; 26: 117-122.
5. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295: 405-418.
6. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086.
7. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 2001; 50: 163-171. (Pubitemid 32701188)
8. Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int Suppl 2009; 112: S62-66.
9. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost 2005; 94: 312-318.
10. Sandvig K. Shiga toxins. Toxicon 2001; 39: 1629-1635. (Pubitemid 32786996)
11. Ling H, Boodhoo A, Hazes B, et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 1998; 37: 1777-1788. (Pubitemid 28099800)
12. Jackson MP, Neill RJ, O'Brien AD, et al. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli. FEMS Microbiol Lett 1987; 44: 109-114.
13. Lingwood CA, Law H, Richardson S, et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 1987; 262: 8834-8839.
14. Waddell T, Head S, Petric M, et al. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun 1988; 152: 674-679.
15. Müthing J, Schweppe CH, Karch H, et al. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost 2009; 101: 252-264.
16. Head SC, Karmali MA, Lingwood CA. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 1991; 266: 3617-3621. (Pubitemid 21909257)
17. Fraser ME, Cherney MM, Marcato P, et al. Binding of adenine to Stx2, the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62: 627-630.
18. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69: 6148-6155. (Pubitemid 32885176)
19. Brigotti M, Caprioli A, Tozzi AE, et al. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic- uremic syndrome. J Clin Microbiol 2006; 44: 313-317. (Pubitemid 43222215)
20. Brigotti M, Carnicelli D, Ravanelli E, et al. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J Leukoc Biol 2008; 84: 1019-1027.
21. Johannes L, Goud B. Facing inward from compartment shores: how many pathways were we looking for? Traffic 2000; 1: 119-123.
22. Sandvig K, van Deurs B. Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin. FEBS Lett 2002; 529: 49-53. (Pubitemid 35283911)
23. Römer W, Berland L, Chambon V, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007; 450: 670-675. (Pubitemid 350207679)
24. Sandvig K, Garred O, Prydz K, et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992; 358: 510-512.
25. Lingwood CA. Aglycone modulation of glycolipid receptor function. Glycoconj J 1996; 13: 495-503. (Pubitemid 26271265)
26. Sandvig K, Spilsberg B, Lauvrak SU, et al. Pathways followed by protein toxins into cells. Int J Med Microbiol 2004; 293: 483-490. (Pubitemid 38667570)
27. Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol 2006; 7: 568-579. (Pubitemid 44325348)
28. Yu M, Haslam DB. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infect Immun 2005; 73: 2524-2532. (Pubitemid 40470856)
29. Garred O, Dubinina E, Holm PK, et al. Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp Cell Res 1995; 218: 39-49.
30. O'Brien AD, Tesh VL, Donohue-Rolfe A, et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992; 180: 65-94.
31. Barbieri L, Valbonesi P, Brigotti M, et al. Shiga-like toxin I is a polynucleotide:adenosine glycosidase. Mol Microbiol 1998; 29: 661-662.
32. Endo Y, Tsurugi K, Yutsudo T, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988, 171: 45-50.
33. Katagiri YU, Mori T, Nakajima H, et al. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent- insoluble microdomains. J Biol Chem 1999; 274: 35278-35282. (Pubitemid 129509587)
34. Takenouchi H, Kiyokawa N, Taguchi T, et al. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J Cell Sci 2004; 117: 3911-3922. (Pubitemid 39207328)
35. Fujii J, Wood K, Matsuda F, et al. Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein. Infect Immun 2008; 76: 3679-3689.
36. Brigotti M, Accorsi P, Carnicelli D, et al. Shiga toxin 1: damage to DNA in vitro. Toxicon 2001; 39: 341-348.
37. Brigotti M, Carnicelli D, Vara AG. Shiga toxin 1 acting on DNA in vitro is a heatstable enzyme not requiring proteolytic activation. Biochimie 2004; 86: 305-309.
38. Sestili P, Alfieri R, Carnicelli D, et al. Shiga toxin 1 and ricin inhibit the repair of H2O2-induced DNA single strand breaks in cultured mammalian cells. DNA Repair 2005; 4: 271-277. (Pubitemid 39601415)
39. Sandvig K, Torgersen ML, Raa HA, et al. Clathrin-independent endocytosis: from nonexisting to an extreme degree of complexity. Histochem Cell Biol 2008; 129: 267-276.
40. Obrig TG, Del Vecchio PJ, Brown JE, et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988; 56: 2373-2378.
41. Louise CB, Obrig TG. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 1995; 172: 1397-1401.
42. Ohmi K, Kiyokawa N, Takeda T, et al. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem Biophys Res Commun 1998; 251: 137-141. (Pubitemid 28498076)
43. Jacewicz MS, Acheson DW, Binion DG, et al. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect Immun 1999; 67: 1439-1444. (Pubitemid 29108526)
44. Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis 1999; 180: 1205-1213. (Pubitemid 30070205)
45. Stins MF, Gilles F, Kim KS. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 1997; 76: 81-90. (Pubitemid 27272632)
46. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80: 3734-3737. (Pubitemid 13063134)
47. Smith HW, Linggood MA. The transmissible nature of enterotoxin production in human enteropathogenic strain of Escherichia coli. J Med Microbiol 1971; 4: 301-305.
48. Strockbine NA, Marques LR, Newland JW, et al. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 1986; 53: 135-140.
49. Petric M, Karmali MA, Arbus GS, et al. Effects of cycloheximide and puromycin on cytotoxic activity of Escherichia coli verocytotoxin (Shiga-like toxin). J Clin Microbiol 1987; 25: 1265-1268.
50. Head SC, Karmali MA, Roscoe ME, et al. Serological differences between verocytotoxin 2 and Shiga-like toxin II. Lancet 1988; 2: 751.
51. Karmali MA, Petric M, Lim C, et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-782. (Pubitemid 15094592)
52. Reichelt R. Scanning Electron Microscopy. In: Science of Microscopy. Springer, 2007. pp. 133-272.
53. Kemper B, Carl D, Höink A, et al. Modular digital holographic microscopy system for marker free quantitative phase contrast imaging of living cells. Proc SPIE 2006; 6191: 61910T.
54. Carl D, Kemper B, Wernicke G, et al. Parameter-optimized digital holographic microscope for high-resolution living-cell analysis. Appl Opt 2004; 43: 6536-6544. (Pubitemid 40120770)
55. Kemper B, Carl D, Schnekenburger J, et al. Investigation of living pancreas tumor cells by digital holographic microscopy. J Biomed Opt 2006; 11: 34005.
56. Kemper B, Bauwens A, Vollmer A et al. Label-free quantitative cell division monitoring of endothelial cells by digital holographic microscopy. J Biomed Opt 2010; 15: 036009.
57. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide and flow cytometry. J Immunol Methods 1991; 139: 271-279.
58. Johannes L, Römer W. Shiga toxins - from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8: 105-116.
59. Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J Infect Dis 2003; 187: 154-158. (Pubitemid 36034486)
60. Schweppe CH, Bielaszewska M, Pohlentz G, et al. Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J 2008; 25: 291-304.
61. Falguières T, Römer W, Amessou M, et al. Functionally different pools of Shiga toxin receptor, globotriaosyl ceramide, in HeLa cells. FEBS J 2006; 273: 5205-5218. (Pubitemid 44673308)
62. Kiarash A, Boyd B, Lingwood CA. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J Biol Chem 1994; 269: 11138-11146.
63. Arab S, Lingwood CA. Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes. Glycoconj J 1996; 13: 159-166. (Pubitemid 26132723)
64. Nakajima H, Kiyokawa N, Katagiri YU, et al. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem 2001; 276: 42915-42922.
65. Binnington B, Lingwood D, Nutikka A, et al. Effect of globotriaosyl ceramide fatty acid α-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem Res 2002; 27: 807-813.
66. Lord JM, Roberts LM. Toxin entry: retrograde transport through the secretory pathway. J Cell Biol 1998; 140: 733-736. (Pubitemid 28141213)
67. Tam P, Mahfoud R, Nutikka A, et al. Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J Cell Physiol 2008; 216: 750-763.
68. Richardson SE, Karmali MA, Becker LE, et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988; 19: 1102-1108.
69. Ostroff SM, Tarr PI, Neill MA, et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 1989; 160: 994-998. (Pubitemid 20002767)
70. Friedrich AW, Bielaszewska M, Zhang W, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74-84.
71. Siegler RL, Obrig TG, Pysher TJ, et al. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 92-96. (Pubitemid 41490292)